Rigel Pharmaceuticals (STU:RI2A) Long-Term Capital Lease Obligation : €0.1 Mil (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Rigel Pharmaceuticals Long-Term Capital Lease Obligation?

Rigel Pharmaceuticals's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.1 Mil.

Rigel Pharmaceuticals's quarterly Long-Term Capital Lease Obligation declined from Sep. 2023 (€0.4 Mil) to Dec. 2023 (€0.3 Mil) and declined from Dec. 2023 (€0.3 Mil) to Mar. 2024 (€0.1 Mil).

Rigel Pharmaceuticals's annual Long-Term Capital Lease Obligation increased from Dec. 2021 (€0.7 Mil) to Dec. 2022 (€0.9 Mil) but then declined from Dec. 2022 (€0.9 Mil) to Dec. 2023 (€0.3 Mil).

Rigel Pharmaceuticals Long-Term Capital Lease Obligation Historical Data

The historical data trend for Rigel Pharmaceuticals's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rigel Pharmaceuticals Long-Term Capital Lease Obligation Chart

Rigel Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

17.31

8.76

0.67

0.92

0.26

Rigel Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															0.75	0.58	0.44	0.26	0.09

Rigel Pharmaceuticals (STU:RI2A) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Rigel Pharmaceuticals Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Rigel Pharmaceuticals's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Rigel Pharmaceuticals (STU:RI2A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rigel Pharmaceuticals Inc (STU:RI2A) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

RIGL:USA

Address

611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080

Website

https://www.rigel.com

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Rigel Pharmaceuticals (STU:RI2A) Headlines

No Headlines